VBIV Stock Price: VBI Vaccines Inc surges as analyst says firm “could have the best coronavirus vaccine”

  • NASDAQ: VBIV is set to surge to the highest levels in a month.
  • Enthusiasm over VBI Vaccines Inc's potent pan-coronavirus immunization candidate is driving shares higher.
  • In a highly competitive race for COVID-19 vaccines, quality may mark a difference.

Vaccinating against more than one coronavirus – and doing it better than competitors – is what VBI Vaccines is seeking. The Massachusets-based pharma firm has performed several preclinical trials on mice and claims that they have provoked a substantial creation of antibodies and other mechanisms to defend against coronaviruses. 

The use of the plural is no mistake – one of the candidates is a "trivalent" pan-coronavirus vaccine, protecting against the raging SARS-Cov-2, the 2003-era SARS-CoV, and also MERS-CoV, which dates back to 2015. 

Another advantage is that VBI's vaccine may require only one shot – allowing faster distribution of immunization to the world population. 

Skeptics have noted that optimism in the preclinical stage may not necessarily translate into success with human subjects. Moreover, several large pharma firms are already conducting Phase 3 tests – injecting their solutions to around 30,000 subjects. 

Nevertheless, the AstraZeneca/University of Oxford project – considered the most advanced – may work for only 12-24 months. With dozens of companies working on a solution – and limited production capacity – there is still time for smaller firms to provide potentially better solutions

The high level of antibodies created – at least among mice – may be a differentiating factor. That has led Steven Seedhouse, an analyst with Raymond James, to upgrade the stock to "strong-buy", adding that "VBI may be in an entirely different ballpark for potency vs. any other vaccine we've seen."

VBIV Stock Forecast

NASDAQ: VBIV is quoted at around $4.50 in Friday's pre-market trading, building on top of its whopping 32% leap on Thursday. VBI Vaccines is on course to hit the highest since late July, a one-month high. The 52-week high of $6.83 is the bullish upside target. Support awaits at $3.19, August's low.

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Feed news Join Telegram

Recommended content

Recommended content

Editors’ Picks

EUR/USD rebounds, steadies above 1.0400

EUR/USD rebounds, steadies above 1.0400

EUR/USD has staged a rebound and reclaimed 1.0400 during the American trading hours on Friday with the US Dollar Index retreating from the multi-week high it set at above 105.60. Nevertheless, the pair remains on track to close the week in negative territory. 


GBP/USD climbs to 1.2050 area, looks to post weekly losses

GBP/USD climbs to 1.2050 area, looks to post weekly losses

GBP/USD reversed its direction and advanced to the 1.2050 area after having dropped to 1.1976 earlier in the day. The pair is still down more than 1% on the day with safe-haven flows dominating the financial markets following the disappointing PMI data from the US.


Gold rebounds above $1,800 as US yields fall sharply

Gold rebounds above $1,800 as US yields fall sharply

Gold has regained its traction and recovered above $1,800 after having slumped to a multi-month low below $1,790. Following the dismal PMI data from the US, the benchmark 10-year US Treasury bond yield is down more than 6% on the day, fueling XAU/USD's rebound.

Gold News

Why traders are rushing to exit positions on Cardano’s ADA price

Why traders are rushing to exit positions on Cardano’s ADA price

Cardano (ADA) price has had its performance review as the summer kicks off. ADA bulls are returning home with not-that-good a scorecard, and the underperformance could cut short holiday funding for the cryptocurrency.

Read more

FXStreet Premium users exceed expectations

FXStreet Premium users exceed expectations

Tap into our 20 years Forex trading experience and get ahead of the markets. Maximize our actionable content, be part of our community, and chat with our experts. Join FXStreet Premium today!